Smith & Nephew Plc
17 December 2002
17 December 2002
STRONG FULL-YEAR RESULTS EXPECTED FOR SMITH & NEPHEW
Medical Devices Company Continues to Sustain Business Growth
Smith & Nephew plc, the advanced medical devices group, has continued to deliver
strong business performance in the second half of the year, with the underlying
rate of sales growth in the ongoing businesses expected to be 14% for the full
year - the same as last year. Acquisitions added a further 4% to this growth,
but currency will be 3% adverse.
Smith & Nephew is to give a trading update to investors and analysts today ahead
of the close period preceding its Preliminary Results announcement. The
company, whose business is focused on the fast-growing markets for orthopaedics,
endoscopy and advanced wound management products, will report its preliminary
results on 7 February 2003 at 2pm GMT (8am CST). Please note that this is a
change from the previously published date in order to present simultaneously to
analysts and investors in London and New Orleans during the American Academy of
Orthopaedic Surgeons meeting.
Smith & Nephew has continued to perform strongly in all of its businesses
throughout 2002. Orthopaedics led the way once again, with underlying sales
expected to grow by 19% for the full year, and extremely strong knee growth at
33% over last year. Endoscopy's underlying sales growth will be 10% for the
full year, with the acquisition of Oratec this year adding 9% to this. Wound
Management will once again deliver underlying sales growth of 11%, with last
year's acquisition of the Beiersdorf and Acticoat ranges adding 4% to this for
the full year.
Chris O'Donnell, Chief Executive of Smith & Nephew said, 'Our innovative
products and the investments we have made in our sales forces are delivering
sustained growth above that of the markets in which we operate. We are pleased
with the progress made by Smith & Nephew this year, and we are focused on
delivering continued sales growth and expanding our group operating margins
moving forward.'
The briefing today will be by conference call at 3pm UK time, and can be heard
by live audio webcast via the Smith & Nephew website www.smith-nephew.com. A
recording of the briefing will be available on the Smith & Nephew website after
the call.
Enquiries
Chris O'Donnell, Chief Executive Tel: +44 (0) 20 7401 7646
Smith & Nephew plc
Peter Hooley, Finance Director Tel: +44 (0) 20 7401 7646
Smith & Nephew plc
Angie Craig, Corporate Affairs Director Tel: +44 (0) 20 7401 7646
Smith & Nephew plc
David Yates Tel: +44 (0) 20 7831 3113
Financial Dynamics
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.